{"entity":{"id":"fn1","kind":"target","name":"FN1","aka":["fibronectin 1","Fibronectin","GFND2","lnc-ABCA12-8"],"tldr":"FN1 (Fibronectin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","summary":"Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonisation, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralisation.\n\nCIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming L19IL2, Dacarbazine and Daromun. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 1.00, affected pathway 0.98, genetic association 0.03, clinical 0.19).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3778","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3778"},{"label":"UniProt P02751","url":"https://www.uniprot.org/uniprotkb/P02751/entry"},{"label":"NCBI Gene 2335","url":"https://www.ncbi.nlm.nih.gov/gene/2335"},{"label":"Ensembl ENSG00000115414","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115414"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.19; CIViC holds 3 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FN1","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3778","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3778","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P02751","url":"https://www.uniprot.org/uniprotkb/P02751/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FN1","url":"https://civicdb.org/features/1947","note":"3 evidence items, 0 assertions, 1 variants; diseases: Melanoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000115414","url":"https://platform.opentargets.org/target/ENSG00000115414/associations","note":"association with cancer (MONDO_0004992) 0.64;  (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FN1: RNA tissue enhanced (blood vessel 2,746 nTPM, liver 1,614 nTPM, placenta 2,752 nTPM); high antibody staining in 4 normal tissues; highest cancer staining pancreatic cancer (3 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas FN1 tissue","url":"https://www.proteinatlas.org/ENSG00000115414-FN1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000115414 associations","url":"https://platform.opentargets.org/target/ENSG00000115414/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3778","ensembl":"ENSG00000115414","uniprot":"P02751","entrez":"2335","firstDescribed":1982,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Pierschbacher M.D. et al, J. Biol. Chem, 1982, \"The cell attachment domain of fibronectin. Determination of the primary structure\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7050098/","biology":"Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonisation, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralisation. Participates in the regulation of type I collagen deposition by osteoblasts. Acts as a ligand for the LILRB4 receptor, inhibiting FCGR1A/CD64-mediated monocyte activation. Binds fibronectin and induces fibril formation. Location: Secreted, extracellular space, extracellular matrix; Secreted (UniProt). Locus 2q35 (HGNC).","whereFound":["Melanoma: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/fn1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}]}}